Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Myeloid 2Lymphoid 1

Conditions

Myelodysplastic Syndromes 170Leukemia, Myeloid, Acute 151Myeloproliferative Disorders 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Primary Myelofibrosis 52Leukemia, Myelomonocytic, Chronic 44Lymphoma, Non-Hodgkin 39Leukemia 27Polycythemia Vera 25Hodgkin Disease 25Thrombocythemia, Essential 22Myelodysplastic-Myeloproliferative Diseases 22Multiple Myeloma 21Leukemia, Lymphocytic, Chronic, B-Cell 20Hematologic Neoplasms 19Neoplasms 17Leukemia, Biphenotypic, Acute 17Anemia, Refractory, with Excess of Blasts 15Sarcoma 13Leukemia, Myeloid, Chronic-Phase 13Histiocytosis, Langerhans-Cell 13Glioma 13Recurrence 12Neuroblastoma 12Hematologic Diseases 12Wilms Tumor 11Rhabdoid Tumor 11Osteosarcoma 11Neuroectodermal Tumors, Primitive, Peripheral 11

Interventions

pegaspargase 1Methylprednisolone 1Etoposide 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphohistiocytosis, Hemophagocytic × Myeloid × 90 days × Clear all
NCT03827343 2026-06-05

Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer

National Institutes of Health Clinical Center (CC)

Active not recruiting
500 enrolled
Myeloid

Lymphohistiocytosis, Hemophagocytic, Macrophage Activation Syndrome

NCT07525466 2026-04-13

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Beijing Tongren Hospital

Phase 1/2 Recruiting
25 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡